Advertisement
Advertisement
PRE
Prenetics Global Limited Class A Ordinary Share
22.97
USDSponsored
+0.04
+0.17%
Sep 25, 15:58 UTC -4
Closed
After-Market
22.95
-0.02
-0.09%
PRE Earnings Reports
Positive Surprise Ratio
PRE beat 7 of 15 last estimates.
47%
Next Report
Date of Next Report
Nov 09, 2026
Estimate for Q3 26 (Revenue/ EPS)
$63.99M
/-$0.75
Implied change from Q2 26 (Revenue/ EPS)
+37.65%
/+41.51%
Implied change from Q3 25 (Revenue/ EPS)
+171.67%
/+41.51%
Prenetics Global Limited Class A Ordinary Share earnings per share and revenue
On Aug 18, 2026, PRE reported earnings of -0.53 USD per share (EPS) for Q2 26, beating the estimate of -0.71 USD, resulting in a 26.30% surprise. Revenue reached 46.49 million, compared to an expected 48.59 million, with a -4.34% difference. The market reacted with a +0.15% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 2 analysts forecast an EPS of -0.75 USD, with revenue projected to reach 63.99 million USD, implying an increase of 41.51% EPS, and increase of 37.65% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AnaptysBio, Inc. Common Stock
Report Date
Sep 21, 2026 For Q2 26
Estimate
$0.00
Actual
$5.11
Surprise
>+10,000.00%
BlossomHill Therapeutics, Inc. Common Stock
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$1.03
Actual
-$8.75
Surprise
-746.56%
Vogenx Inc Common Stock
Report Date
Sep 17, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.07
Surprise
+1.96%
Benitec Biopharma Inc. Common Stock
Report Date
Sep 14, 2026 For Q4 26
Estimate
-$0.27
Actual
-$0.26
Surprise
+5.59%
Abivax SA - ADR
Report Date
Sep 21, 2026 For Q2 26
Estimate
-$1.82
Actual
-$2.09
Surprise
-14.47%
AYTU BioPharma, Inc. Common Stock
Report Date
Sep 22, 2026 For Q4 26
Estimate
-$0.33
Actual
-$0.05
Surprise
+84.92%
Neuphoria Therapeutics Inc. Common Stock
Report Date
Sep 18, 2026 For Q4 26
Estimate
-$0.57
Actual
-$0.95
Surprise
-66.32%
NewcelX Ltd. Ordinary Shares
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$0.54
Actual
-$0.96
Surprise
-77.58%
FAQ
What were Prenetics Global Limited Class A Ordinary Share's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Prenetics Global Limited Class A Ordinary Share reported EPS of -$0.53, beating estimates by 26.3%, and revenue of $46.49M, -4.34% below expectations.
How did the market react to Prenetics Global Limited Class A Ordinary Share's Q2 2026 earnings?
The stock price moved up 0.15%, changed from $19.37 before the earnings release to $19.40 the day after.
When is Prenetics Global Limited Class A Ordinary Share expected to report next?
The next earning report is scheduled for Nov 09, 2026.
What are the forecasts for Prenetics Global Limited Class A Ordinary Share's next earnings report?
Based on 2
analysts, Prenetics Global Limited Class A Ordinary Share is expected to report EPS of -$0.75 and revenue of $63.99M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.